CORRECTING and REPLACING LabConnect Elects Eric Richman as Chairman of the Board
Sep. 06, 2018
SEATTLE--(BUSINESS WIRE)--Sep 6, 2018--Please replace the release dated September 5, 2018 with the following corrected version due to multiple revisions.
The corrected release reads:
LABCONNECT ELECTS ERIC RICHMAN AS CHAIRMAN OF THE BOARD
LabConnect, LLC, a leading global provider of central laboratory and support services for biopharmaceutical, medical device and contract research organizations, today announced that its Board of Directors has elected Eric I. Richman as Chairman of the Board.
“I’m delighted Eric has accepted the role of Chairman of LabConnect,” stated Eric Hayashi, president and CEO of LabConnect. “Eric brings with him an insider’s knowledge of the needs of our biopharmaceutical clients and I look forward to a close relationship with him as we write the next chapter of LabConnect’s story together.”
Mr. Richman will succeed Alain Chetrit, LabConnect cofounder and chairman, who will now serve as Chairman emeritus. During his tenure as Board Chairman, LabConnect experienced sustained compound annual growth of more than 30%. “I am proud to have had the opportunity to create and contribute to a thriving organization that betters lives, and I’m confident that Eric will help guide the company on a similar trajectory,” noted Mr. Chetrit.
“On behalf of the entire Board, I’d like to express our sincere gratitude to Alain for his dedicated service to LabConnect,” said incoming chairman, Eric Richman. “Alain has guided the company through a period of unparalleled growth.”
Mr. Richman has more than 25 years of experience as a life science executive and has been instrumental in the growth and success of a number of life science companies. As a member of the founding team of MedImmune, his responsibilities included the commercial launches of rare disease and oncology products, and he served in various roles in strategic planning, business development and international operations. From 2007 through 2015, Mr. Richman was president & CEO of PharmAthene, Inc. Mr. Richman has been a Director of LabConnect since 2017 and also serves on the Boards of ADMA Biologics (NASDAQ: ADMA), and NovelStem, Inc. Former Board roles include PharmAthene, Inc., LEV Pharmaceuticals, Tyrogenex, Inc., Siga Technologies, and American Bank.
About LabConnect, LLC Founded in 2002, LabConnect provides global central laboratory and client-inspired support services including routine and specialized laboratory testing, kit building, sample management, data management, biorepository and scientific support services for biopharmaceutical and CRO clients. LabConnect’s unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets and extensive specialized testing expertise means that drug development companies can rely on one provider for their central laboratory and preclinical through Phase IV clinical development needs. Learn more at labconnectllc.com or connect with LabConnect on LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180905005156/en/
CONTACT: LabConnect, LLC
Jaimy McCarthy, 206-322-4680
KEYWORD: UNITED STATES NORTH AMERICA WASHINGTON
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: LabConnect, LLC
Copyright Business Wire 2018.
PUB: 09/06/2018 02:55 PM/DISC: 09/06/2018 02:55 PM